Repligen beats estimates as bioprocessing recovery gains traction
Compartilhar
Repligen (NASDAQ:RGEN) reported fourth-quarter results that surpassed analyst forecasts, providing fresh evidence that the bioprocessing industry is successfully moving past its post-pandemic destocking phase.
